Ocular Therapeutix (OCUL) stock rises as its Phase 3 trial for lead asset Axpaxli in wet AMD nears enrollment target. Read ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...

Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.

Individualization of anti-VEGF treatment protocols can reduce treatment burden on patients with age-related macular degeneration ... hemorrhages or fluid seen on OCT images.

Patients with neovascular age-related macular degeneration (nAMD ... and intraretinal fluid (IRF). Optical coherence tomography was taken as well. There were 35 eyes from 35 patients that were ...

Patients with treatment-recalcitrant neovascular age-related macular degeneration (nAMD ... endothelial growth factor (VEGF) drugs, maintain stable vision and experience significant improvements in ...

Optical coherence tomography ... the critical role of VEGF in embryonic development and how it can get out of control in conditions like age-related macular degeneration (AMD), retinal vein ...

Age-related macular degeneration (AMD), an acquired retinal disease ... or informing treatment decisions include optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), ...

Background/Aims Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD ... Germany), and spectral domain optical coherence ...